The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in Thailand
Abstract
BACKGROUND: Although zidovudine prophylaxis decreases the rate of transmission of the human immunodeficiency virus (HIV) type 1 substantially, a large number of infants still become infected. We hypothesized that the administration, in addition to zidovudine, of a single dose of oral nevirapine to mothers during labor and to neonates would further reduce transmission of HIV. METHODS: We conducted a randomized, double-blind trial of three treatment regimens in Thai women who were receiving zidovudine therapy during the third trimester of pregnancy. In one group, mothers and infants received a single dose of nevirapine (nevirapine-nevirapine regimen); in another, mothers and infants received nevirapine and placebo, respectively (nevirapine-placebo regimen); and in the last, mothers and infants received placebo (placebo-placebo regimen). The infants also received one week of zidovudine therapy and were formula-fed. The end point of the study was infection with HIV in the infants, established by virologic testing. RESULTS: Between January 15, 2001, and February 28, 2003, a total of 1844 Thai women were enrolled. At the first interim analysis, the independent data monitoring committee stopped enrollment in the placebo-placebo group. Among women who delivered before the interim analysis, the as-randomized Kaplan-Meier estimates of the transmission rates were 1.1 percent (95 percent confidence interval, 0.3 to 2.2) in the nevirapine-nevirapine group and 6.3 percent (95 percent confidence interval, 3.8 to 8.9) in the placebo-placebo group (P<0.001). The final per-protocol transmission rate in the nevirapine-nevirapine group, 1.9 percent (95 percent confidence interval, 0.9 to 3.0), was not significantly inferior to the rate in the nevirapine-placebo group (2.8 percent; 95 percent confidence interval, 1.5 to 4.1). Nevirapine had an effect within subgroups defined by known risk factors such as viral load and CD4 count. No serious adverse effects were associated with nevirapine therapy. CONCLUSIONS: A single dose of nevirapine to the mother, with or without a dose of nevirapine to the infant, added to oral zidovudine prophylaxis starting at 28 weeks' gestation, is highly effective in reducing mother-to-child transmission of HIV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311801 · Cited by 3,705
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199504000-00002 · Cited by 1,816
Cooper, E. R., Charurat, M., Mofenson, L., Hanson, I. C., Pitt, J., Diaz, C., Hayani, K., Handelsman, E., Smeriglio, V., Hoff, R., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200204150-00009 · Cited by 1,058
Sperling, R. S., Shapiro, D. E., Coombs, R. W., Todd, J. A., Herman, S. A., McSherry, G. D., O'Sullivan, M. J., Van Dyke, R. B., Jimenez, E., Rouzioux, C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352201 · Cited by 803
Mofenson, L. M., Lambert, J. S., Stiehm, E. R., Bethel, J., Meyer, W. A., Whitehouse, J., Moye, J., Reichelderfer, P., Harris, D. R., Fowler, M. G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410601 · Cited by 547
Wade, N. A., Birkhead, G. S., Warren, B. L., Charbonneau, T. T., French, P. T., Wang, L., Baum, J. B., Tesoriero, J. M., & Savicki, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811123392001 · Cited by 535
Cited by
Coovadia, H. M., Rollins, N. C., Bland, R. M., Little, K., Coutsoudis, A., Bennish, M. L., & Newell, M.-L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60283-9 · Cited by 702
Nachega, J. B., Uthman, O. A., Anderson, J., Peltzer, K., Wampold, S., Cotton, M. F., Mills, E. J., Ho, Y.-S., Stringer, J. S. A., McIntyre, J. A., et al. (2012) · AIDS · doi:10.1097/qad.0b013e328359590f · Cited by 488
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission
Chasela, C. S., Hudgens, M. G., Jamieson, D. J., Kayira, D., Hosseinipour, M. C., Kourtis, A. P., Martinson, F., Tegha, G., Knight, R. J., Ahmed, Y. I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911486 · Cited by 440
Thior, I., Lockman, S., Smeaton, L. M., Shapiro, R. L., Wester, C., Heymann, S. J., Gilbert, P. B., Stevens, L., Peter, T., Kim, S., et al. (2006) · JAMA · doi:10.1001/jama.296.7.794 · Cited by 413
Self-citationRuxrungtham, K., Brown, T., & Phanuphak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16593-8 · Cited by 398
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection
Volmink, J., Siegfried, N., van der Merwe, L., & Brocklehurst, P. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003510.pub2 · Cited by 396
Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort
Warszawski, J., Tubiana, R., Le Chenadec, J., Blanche, S., Teglas, J.-P., Dollfus, C., Faye, A., Burgard, M., Rouzioux, C., & Mandelbrot, L. (2008) · AIDS · doi:10.1097/qad.0b013e3282f3d63c · Cited by 350
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection
Siegfried, N., van der Merwe, L., Brocklehurst, P., & Sint, T. T. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003510.pub3 · Cited by 325
Galea, J. T., Kinsler, J. J., Salazar, X., Lee, S.-J., Giron, M., Sayles, J. N., Cáceres, C., & Cunningham, W. E. (2011) · International Journal of STD & AIDS · doi:10.1258/ijsa.2009.009255 · Cited by 180
Metadata
- Authors
- Lallemant, M., Jourdain, G., Le Coeur, S., Mary, J. Y., Ngo-Giang-Huong, N., Koetsawang, S., Kanshana, S., McIntosh, K., & Thaineua, V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-07-15
- Volume
- 351
- Issue
- 3
- Pages
- 217-228
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2147072996
- Cited by
- 460
- References
- 23
- FWCI
- 30.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.